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Background: This phase II study evaluated single-agent bosutinib in pretreated patients with locally advanced or
metastatic breast cancer.
Patients and methods: Patients received oral bosutinib 400 mg/day. The primary end point was the progression-
free survival (PFS) rate at 16 weeks. Secondary end points included objective response rate, clinical benefit rate,
2-year overall survival rate, safety, and changes in levels of bone resorption/formation biomarkers.
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Results: Seventy-three patients were enrolled and treated. Median time from diagnosis of metastatic disease to
initiation of bosutinib treatment was 24.5 months. For the intent-to-treat population, the PFS rate at 16 weeks was
39.6%. Unexpectedly, all responding patients (n = 4) were hormone receptor positive. The clinical benefit rate was
27.4%. The 2-year overall survival rate was 26.4%. The main toxic effects were diarrhea (66%), nausea (55%), and
vomiting (47%). Grade 3–4 laboratory aminotransferase elevations occurred in 14 (19%) patients. Myelosuppression
was minimal. No consistent changes in the levels of bone resorption/formation biomarkers were seen.
Conclusions: Bosutinib showed promising efficacy in prolonging time to progression in chemotherapy-pretreated
patients with locally advanced or metastatic breast cancer. Bosutinib was generally well tolerated, with a safety profile
different from that of the Src/Abl tyrosine kinase inhibitor dasatinib in a similar patient population.
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introduction
Despite recent progress in the management of early breast
cancer, nearly half of women with breast cancer develop
metastatic disease [1]. The median survival of patients with
metastatic breast cancer has improved over the last decade to
36 months, but 10-year survival rates remain low, at only 5%–
10% [2]. Treatment is therefore aimed at symptom palliation,
improving quality of life, inhibiting disease progression, and
improving survival. Due to a recent shift in treatment
protocols, aggressive cytotoxic drugs like anthracyclines and
taxanes are being used earlier in the course of the disease [3].
After patients have failed treatment with these agents, it is
a challenge to identify active agents for this patient
population.
Besides standard cytotoxic treatments, targeted therapies
have now been developed to treat metastatic disease. The
overexpression of human epidermal growth factor receptor 2
(HER2) is a well-recognized prognostic factor of tumor
aggressiveness and poor survival. However, HER2 is also
a therapeutic target for trastuzumab, a recombinant
humanized antibody that binds to the receptor’s extracellular
domain. Treatment of patients with HER2-positive metastatic
breast cancer with trastuzumab led to a 44% decrease in the
risk of death compared with HER2-negative patients [4].
Resistance occurs, however, and the current challenge is to
bypass such resistance by targeting alternative tumor growth
pathways.
Tyrosine kinases are therapeutic targets for small-molecule
inhibitors. Bosutinib (SKI-606) is a substituted 4-anilino-3-
quinoline carbonitrile and a selective dual inhibitor of Src and
Abl tyrosine kinases [5–7]. Src kinase is a key component of
pathways mediated by growth factor receptors [8] and is
involved in the function of osteoclasts [9, 10]. Elevations of Src
kinase activity have been reported in a wide variety of tumor
types [8]. In human breast cancer, elevated Src kinase activity
has been found in 70% of the samples examined [11]. In
preclinical studies, bosutinib inhibited the proliferation,
migration, and invasion of cells of a highly invasive breast
cancer cell line and also tumor growth and metastasis of these
cells in a xenograft mouse model [7].
Based on the effects of bosutinib in human breast cancer
cells in preclinical studies, a phase I study in patients with
advanced solid tumors was conducted to identify
a maximum tolerated dose. Bosutinib was generally well
tolerated, and stable disease (SD) was observed in patients
with various primary tumor types [12]. Thus, we conducted
a phase II study of bosutinib in pretreated patients with
locally advanced or metastatic breast cancer to further
evaluate efficacy and safety. In addition, because Src kinase
plays a key role in osteoclast function and osteoclasts are
primarily involved in osteolytic metastatic bone disease [13–
15], a common aspect of breast cancer, we monitored bone
resorption and formation biomarkers.
patients and methods
study population
Patients of at least 18 years of age with a pathological diagnosis of breast
cancer and current stage IIIB, IIIC, or IV disease, not curable with available
therapies, were eligible. Patients had to have disease progression after one to
three prior chemotherapy regimens for locally advanced or metastatic
disease and at least one measurable lesion as defined by modified RECIST
(version 1.0) [16]. Other eligibility criteria included a Karnofsky
performance status of at least 70% that had not declined within 4 weeks
before the first dose of bosutinib; a life expectancy of at least 16 weeks;
serum calcium levels £3.1 mmol/l; adequate hematologic, renal, cardiac,
and hepatic functions; and ability to swallow whole capsules. Patients were
not eligible if bisphosphonates, which inhibit bone resorption, had been
used within 8 weeks before the first dose of bosutinib; if they had received
prior therapy with a Src kinase inhibitor; or if they had extensive visceral
disease, symptomatic or clinically active central nervous system metastases,
or skin or bone as the only site of disease.
Written informed consent was obtained before enrollment. The protocol
was reviewed and approved by the Ethics Committees/Institutional Review
Boards of the participating institutions and the study was conducted
according to the Declaration of Helsinki and European Good Clinical
Practice requirements.
treatment
Bosutinib (Pfizer Inc, New York, NY) 500 mg was identified as the
maximum tolerated dose in a phase I dose escalation study in patients with
solid tumors, but 400 mg was the recommended dose because a number of
patients who were treated with 500 mg had grade 2 gastrointestinal toxic
effects [12]. Bosutinib was given orally as a single dose of 400 mg/day.
Patients remained on treatment for as long as treatment was tolerated or
until there was evidence of disease progression.
Bosutinib treatment was withheld if grade 2 or 3 (National Cancer
Institute—Common Terminology Criteria for Adverse Events, version 3.0)
diarrhea occurred and lasted for >2 days despite optimal medical therapy
or was associated with fever or dehydration, or if a grade 3 or 4
nonhematologic adverse event occurred, or if a grade 4 hematologic event
occurred. Upon recovery to grade 1 or the baseline condition within
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3 weeks, bosutinib treatment was restarted at a reduced dose of 300 mg/day.
Patients who failed to recover to grade 1 or the baseline condition after
3 weeks discontinued bosutinib treatment. More than one dose reduction
was not permitted unless discussed with the sponsor.
efficacy assessment
Screened patients underwent contrast-enhanced computed tomography
scans or magnetic resonance imaging at baseline and at study weeks 4, 8,
and 16 and then every 8 weeks thereafter until disease progression. A
patient was considered assessable if she met all eligibility criteria, had
completed at least 14 days of treatment with bosutinib, and had
a screening scan and at least one follow-up scan after starting treatment.
Patients whose disease clinically progressed or who died early and for
whom a postbaseline assessment was not possible were considered
assessable for efficacy.
safety assessment
Patients receiving at least one dose of bosutinib were assessable for
safety. Safety was assessed by physical examination, laboratory tests,
electrocardiogram measurements, and adverse events reports. Safety
follow-up continued until resolution of any drug-related toxicity.
Patients with documented disease progression discontinued bosutinib
treatment.
bone turnover assessment
The bone resorption biomarkers, crosslinked N-telopeptide of type I
collagen and crosslinked C-telopeptide of type I collagen (CTX), and the
bone formation biomarkers bone-specific alkaline phosphatase (BSAP),
osteocalcin, and procollagen type 1 aminoterminal propeptide (P1NP) were
analyzed. Serum and urine samples were collected at baseline; weeks 4, 12,
and 24; and then every 8 weeks thereafter to measure biomarker levels.
Measurements were carried out independently by a central laboratory
(Quest Diagnostics, West Hills, CA).
statistical analysis
This was an open-label, two-stage, phase II trial. The primary efficacy end
point was the progression-free survival (PFS) rate at 16 weeks. The null
hypothesis was that the PFS rate at 16 weeks was not >20%. The alternative
hypothesis was that the rate was not <40%. A type I error rate of 0.05 and
a type II error rate of 0.15 gave a sample size of 51 assessable patients, using
an optimal Simon two-stage design [17]. To obtain 51 assessable patients,
assuming a nonevaluable rate of 15%, 60 patients were to be accrued. The
primary analysis of the PFS rate at 16 weeks was to be based on the intent-
to-treat (ITT) population, the total number of enrolled and treated
patients.
Secondary end points included the objective response rate [ORR, the
percentage of patients with confirmed complete response (CR) plus
confirmed partial response (PR)], the clinical benefit rate (the percentage of
patients with confirmed CR and PR and SD lasting longer than 24 weeks),
the 2-year overall survival rate, the safety profile, and pharmacodynamic
analysis of bosutinib activity on bone. Prespecified subgroup analyses were
carried out based on hormone receptor (HR) and HER2 tumor status. This
status was determined from medical histories or, if unknown, attempts were
made to obtain tumor samples for identification of status by a central
laboratory.
PFS was defined as the time from first day of treatment until the first
documented date of progression or death due to any cause. Overall survival
was defined as the time from first day of treatment until death due to any
cause. Patients who were alive at the time of last contact were censored. PFS
and the 2-year overall survival rate were computed according to the
Kaplan–Meier method.
results
characteristics of patients and treatment
From June 2006 to January 2007, 73 patients from 15 centers in 8
countries were enrolled and treated with at least one dose of
bosutinib (Figure 1). The baseline characteristics of patients are
summarized in Table 1. At baseline, 72 patients had metastatic
disease and 1 patient had stage IIIC disease. Seventy-eight percent
of patients had received one to three prior regimens
(chemotherapy, immunotherapy, and/or hormonal therapy)
for their locally advanced or metastatic disease; all patients had
received at least one chemotherapy regimen and 51% had received
at least one hormonal therapy regimen. The median time from
first diagnosis of locally advanced or metastatic disease to first dose
of bosutinib was 24.5 months (range, 2.7 months–17.6 years).
Sixty-six (91%) patients received at least 14 days of bosutinib
treatment; among them, two (3%) received bosutinib beyond
12 months. The median dose received was 400 mg per day
(range, 308–400 mg). The median duration of treatment was
9.9 weeks (range, 3 days–77 weeks).
efficacy
For the ITT population, the PFS rate at 16 weeks was 39.6%
(95% confidence interval [CI] 28.1%–50.8%) and the median
PFS was 9.9 weeks (95% CI 6.7–16.7 weeks; Figure 2A). For
patients with HR-positive disease (n = 49), the PFS rate at 16
weeks was 43.1% (95% CI 28.8%–56.5%); for those with
HER2-positive disease (n = 12), the rate was 41.7% (95% CI
15.2%–66.5%); and for those with triple-negative disease
(negative for estrogen and progesterone receptors and HER2;
n = 13), the rate was 25.0% (95% CI 6.0%–50.5%). Similar
results were obtained for the evaluable population (Figure 2B).
The best overall responses and clinical benefit rates for the
ITT and evaluable populations are summarized in Table 2. In
the ITT population, no patients achieved a CR and four
patients achieved a confirmed PR for an ORR of 5.5%. All the
confirmed PRs were in the subset of patients with HR-positive
disease (HR positive/HER2 negative, n = 3; HR positive/HER2
unclassified, n = 1) for an ORR of 8.2%. Twenty-four patients
had SD, and 16 of these had duration of >24 weeks for a clinical
benefit rate of 27.4%. Twelve of the 16 patients with SD beyond
Figure 1. Study flowchart.
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24 weeks had HR-positive disease for a clinical benefit rate of
32.7% in that subgroup. For patients with HER2-positive
disease (n = 12), the clinical benefit rate was 25.0%. The median
duration of response for the four patients with a confirmed PR
was 37.1 weeks (range, 16.1–61.6 weeks).
The maximum percent reduction in target tumor sizes, based
on HR and HER2 status, is presented in Figure 3. Of 59 patients
assessable for efficacy who had target lesions assessed at baseline
and at least one follow-up, 46% (n = 27) had a decrease in target
tumor size. In subgroups of patients, 57% (n = 4/7) with HR-
positive/HER2-positive disease, 48% (n = 13/27) with HR-
positive/HER2-negative disease, 0% (n = 0/3) with HR-
negative/HER2-positive disease, and 30% (n = 3/10) with
triple-negative disease had maximum decreases in target
tumor size.
At the time of final analysis, March 2009, 47 (64%) patients
had died, 46 from disease progression and 1 from suicide
believed to be unrelated to bosutinib. The 2-year overall
survival rate for the ITT population was 26.4% (95% CI 14.7%
to 39.7%) and for the evaluable population was 29.3% (95% CI
16.3% to 43.6%).
safety
Seventy-one (97%) of the 73 treated patients experienced
treatment-emergent adverse events (TEAEs), any grade, during
bosutinib treatment. The most common TEAEs were diarrhea
(66% patients), nausea (55%), and vomiting (47%, Table 3). Of
those patients who had diarrhea, most had grade 1 events as the
maximum toxicity (grade 1, 65% patients; grade 2, 27%; grade 3,
Table 1. Baseline characteristics of patients
Characteristic Number of
patients
(N = 73)
Percent
Median age (range), years 54 (33–71)
Karnofsky performance status (%)
>70 65 89
‡60 and £70 8 11
Breast cancer stage at screening
IIIC 1 1
IV 72 99
Number of metastatic sites
1 40 55
2 23 32
‡3 10 14
Primary sites of diseasea
Liver 31 42
Lymph nodes 18 25
Lung 13 18
Breast 7 10
Brain 1 1
Skin 1 1
Other 2 3
HR status and HER2 status
HR+, HER2+ 7 10
HR+, HER22 32 44
HR+, HER2 unclassified 10 14
HR2, HER2+ 5 7
HR2, HER22 13 18
HR unclassified, HER22 1 1
HR unclassified, HER2 unclassified 5 7
Prior adjuvant/neoadjuvant therapy 50 68
Number of prior chemotherapy,
immunotherapy, and hormonal
regimens for locally advanced or
metastatic disease
1–3 57 78
>3 16 22
At least one chemotherapy regimen 73 100
At least one
hormonal therapy regimen
37 51
Median time from first diagnosis of locally
advanced or metastatic disease to first
bosutinib dose (range)
24.5 months
(2.7 months–
17.6 years)
aMost frequent location per patient or location with longest diameter (if
number of locations is the same).
HR, hormone receptor (estrogen and/or progesterone receptor); HER2,
human epidermal growth factor receptor 2.
Figure 2. Kaplan–Meier estimates of progression-free survival (PFS) of
(A) the ITT population and (B) the evaluable population. PFS for the
HR-positive and HER2-positive subgroups is not mutually exclusive.
ITT, intent-to-treat; PFS, progression-free survival; HR, hormone
receptor (estrogen and/or progesterone receptor); HER2, human
epidermal growth factor receptor 2; PFS16, progression-free survival
rate at 16 weeks; Eval, evaluable.
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8%). Onset of diarrhea occurred early during bosutinib
treatment (median, 2 days) and the incidence and severity
decreased over time (Figure 4). Less than 20% of patients had
diarrhea in week 2 or later. No grade 3 diarrhea occurred after
month 1. Five patients had a dose reduction due to diarrhea and
one patient terminated bosutinib treatment due to diarrhea.
During bosutinib treatment, 12 (16%) patients had grade 3–4
elevations in alanine aminotransferase (ALT) levels and 10
(14%) patients had grade 3–4 elevations in aspartate
aminotransferase (AST) levels (14 patients had grade 3–4
elevations in ALT and/or AST levels) as measured by laboratory
tests. Grade 1 elevations occurred in the greatest percentage of
patients as the maximum toxicity (ALT: grade 1, 25%; grade 2,
8%; grade 3, 12%; grade 4, 4%; AST: grade 1, 26%; grade 2,
11%; grade 3, 12%; grade 4, 1%). Elevations of ALT or AST
were generally observed within the first 4 months of bosutinib
Table 2. Best overall response and clinical benefit rates
Response Total HR+a HER2+a HR+/HER22 HR2/HER22 Unclassifiedb
Intent-to-treat population
Number of patients 73 49 12 32 13 6
PR, n (%) 4 (5.5) 4 (8.2) 0 3 (9.4) 0 0
SDc, n (%) 24 (32.9) 17 (34.7) 5 (41.7) 7 (21.9) 3 (23.1) 3 (50.0)
SD £24 weeksd 8 (11.0) 5 (10.2) 2 (16.7) 2 (6.3) 2 (15.4) 0
SD >24 weeksd 16 (21.9) 12 (24.5) 3 (25.0) 5 (15.6) 1 (7.7) 3 (50.0)
Clinical benefit
rate, % (95% CI)
27.4 (17.6%–39.1%) 32.7 (19.9%–47.5%) 25.0 (5.5%–57.2%) 25.0 (11.5%–43.4%) 7.7 (0.2%–36.0%) 50.0 (11.8%–88.2%)
PD, n (%) 36 (49.3) 22 (44.9) 6 (50.0) 17 (53.1) 9 (69.2) 2 (33.3)
Unknown, n (%) 18 (24.7) 12 (24.5) 2 (16.7) 9 (28.1) 2 (15.4) 2 (33.3)
Evaluable population
Number of patients 64 44 12 29 11 4
PR, n (%) 4 (6.3) 4 (9.1) 0 3 (10.3) 0 0
SDc, n (%) 24 (37.5) 17 (38.6) 5 (41.7) 7 (24.1) 3 (27.3) 3 (75.0)
SD £24 weeksd 8 (12.5) 5 (11.4) 2 (16.7) 2 (6.9) 2 (18.2) 0
SD >24 weeksd 16 (25.0) 12 (27.3) 3 (25.0) 5 (17.2) 1 (9.1) 3 (75.0)
Clinical benefit
rate, % (95% CI)
31.3 (20.2%–44.1%) 36.4 (22.4%–52.2%) 25.0 (5.5%–57.2%) 27.6 (12.7%–47.2%) 9.1 (0.2%–41.3%) 75.0 (19.4%–99.4%)
PD, n (%) 33 (51.6) 21 (47.7) 6 (50.0) 17 (58.6) 8 (72.7) 1 (25.0)
Unknown, n (%) 5 (7.8) 3 (6.8) 2 (16.7) 3 (10.3) 0 0
aThe subgroups are not mutually exclusive.
bBoth HR and HER2 status were unknown.
cThe criteria for SD must have been met at least once at a minimum of 8 weeks (window of 22 days) after start of treatment.
dSD at 24 weeks is defined from the start of treatment (window of 22 weeks) until 24 week duration.
HR, hormone receptor (estrogen and/or progesterone receptor); HER2, human epidermal growth factor receptor 2; PR, partial response; SD, stable disease;
CI, confidence interval; PD, progressive disease.
Figure 3. The best response for target lesions per patient for patients with target lesions assessed at baseline and at least one follow-up (n = 59). Patients
with a negative maximum percent reduction from baseline had a decrease in the size of the target tumor and patients with a positive maximum percent
reduction from baseline had an increase in tumor size. HR, hormone receptor (estrogen and/or progesterone receptor); HER2, human epidermal growth
factor receptor 2; U, unclassified.
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treatment, with no grade 3–4 elevations occurring after 4
months of treatment (Figure 5). Of the 14 patients with grade
3–4 ALT and/or AST elevations, 6 (43%) had at least one liver
lesion identified at baseline. Thirteen (93%) patients
recovered to normal or grade 1 levels during bosutinib
treatment or during follow-up after treatment
discontinuation; 8 (57%) patients recovered to normal or
grade 1 levels without bosutinib dose delay or reduction. No
follow-up information was available for one patient, who
discontinued due to disease progression in the lungs and
liver. One patient terminated bosutinib treatment due to
a grade 4 ALT elevation, which resolved to grade 1 within 3
weeks of stopping treatment.
Four (6%) patients had anemia and two (3%) had
neutropenia, both of which were considered unrelated to
bosutinib treatment by investigators. Thrombocytopenia was
not reported. Eight (11%) patients had peripheral edema; one
patient was considered to have edema related to bosutinib
treatment. Two (3%) patients had pleural effusion that was
considered unrelated to bosutinib treatment.
A single dose reduction of bosutinib was required for eight
(11%) patients because of adverse events. Eighteen (25%)
patients had at least one dose delay lasting 3 or more days
because of adverse events. Patients discontinued bosutinib
treatment because of disease progression (75%), adverse events
(12%), withdrawal of consent (7%), death (3%), symptomatic
deterioration (1%), and a failure to return (1%; Figure 1).
bone turnover analysis
The bone resorption marker CTX and the bone formation
markers BSAP, osteocalcin, and P1NP were consistently higher
in patients with bone disease than in those with no bone disease
(data not shown). However, no consistent changes in levels of
each marker relative to time or direction of change during
bosutinib treatment were observed (data not shown).
discussion
In this phase II study, unselected pretreated patients with
locally advanced or metastatic breast cancer were treated with
a single daily oral dose of bosutinib 400 mg. Bosutinib had
moderate antitumor activity. In the ITT population, the
primary end point, the PFS rate at 16 weeks, was 39.6% and
median PFS was 9.9 weeks. The PFS rate at 16 weeks was 25.0%,
41.7%, and 43%, respectively, for patients with triple-negative,
HER2-positive, and HR-positive disease. Four patients with
HR-positive disease achieved a confirmed PR.
These results compare favorably with those of another small-
molecule Src/Abl inhibitor, dasatinib, which has been studied
in two phase II trials as a treatment of metastatic breast cancer
patients who had triple-negative or HR-positive and/or HER2-
positive disease [18, 19]. In both trials, >90% of patients had
received no more than two prior chemotherapy regimens. The
PFS rate at 17 weeks was 14%–22%. Two patients with HR-
positive disease, one with HER2-positive disease, and two with
triple-negative disease had confirmed PRs. While direct
comparisons of clinical trials must be interpreted with caution
because of differences in patient populations, the results of our
study suggest that bosutinib showed at least comparable
Table 3. Treatment-emergent adverse events reported in at least 10% of
the 73 treated patients
Adverse event, n (%) Any grade Grade 3–4
Diarrhea 48 (66) 4 (6)
Nausea 40 (55) 1 (1)
Vomiting 34 (47) 1 (1)
Fatigue 19 (26) 3 (4)
Asthenia 14 (19) 4 (6)
Anorexia 14 (19) 0
Infections and infestations 12 (16) 2 (3)
Rash 10 (14) 0
Headache 10 (14) 1 (1)
Arthralgia 9 (12) 1 (1)
Abdominal pain 9 (12) 1 (1)
Back pain 9 (12) 3 (4)
Peripheral edema 8 (11) 0
Cough 8 (11) 0
Dyspnea 8 (11) 0
Weight decreased 8 (11) 0
Figure 4. Occurrence of diarrhea per time period. The maximum grade toxicity per time period was reported for each patient. W, weeks; M, months.
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efficacy to dasatinib in pretreated metastatic breast cancer
patients with HR-positive disease.
Bosutinib was generally tolerable in this patient population,
with a different toxicity profile from that of dasatinib. Although
diarrhea and fatigue were common toxic effects of both bosutinib
and dasatinib [18, 19], the incidence of anemia in metastatic
breast cancer patients treated with bosutinib (6%) was much
lower than that in similar patients treated with dasatinib (66%)
[18]. Similarly, the incidence of neutropenia in bosutinib-treated
patients (3%) was much lower than in dasatinib-treated patients
(41%). Bosutinib-related peripheral edema was reported in one
(1%) patient and pleural effusion was reported in no patients. In
contrast, dasatinib-related generalized edema and pleural
effusion were reported in 7% and 26%–39% of patients,
respectively [18, 19]. Bosutinib induced reversible elevations in
ALT and AST in this study, which has not been reported for
dasatinib-treated patients [18, 19].
The different toxic effects associated with bosutinib or
dasatinib treatment could be explained by the different
specificities of the drugs. Bosutinib specifically inhibits the Src
and Abl tyrosine kinases, while dasatinib inhibits these as
well as c-Kit and platelet-derived growth factor receptor
(PDGFR)-b [20, 21]. Because c-Kit has a role in normal
hematopoiesis [22], the inhibition of c-Kit by dasatinib may
explain the much higher incidence of anemia and neutropenia
in dasatinib-treated breast cancer patients than in similar
bosutinib-treated patients. Furthermore, the role of PDGFR-b
in the control of tissue interstitial fluid pressure [23] may
explain why fluid accumulation occurred in many more
dasatinib-treated breast cancer patients than in similar
bosutinib-treated ones.
Capecitabine has been used for the treatment of metastatic
breast cancer patients who have previously received treatment
with anthracyclines and/or taxanes and at least two prior
chemotherapy regimens. Synergy has been shown to exist
between dasatinib and capecitabine in triple-negative breast
cancer cell lines [24]. Thus, a phase I/II study is ongoing to
evaluate the combination of bosutinib and capecitabine in
patients with solid tumors (http://ClinicalTrials.gov).
In conclusion, bosutinib as a monotherapy showed
a tolerable safety profile and moderate antitumor activity in
pretreated patients with locally advanced or metastatic breast
cancer. PRs were observed in patients with HR-positive disease.
Given these results in a challenging unselected patient
population, further studies with bosutinib in combination with
other agents are warranted following implementation of an
appropriate method of patient selection.
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Figure 5. Elevations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) per time period. The maximum grade elevation per time
period was reported for each patient. Per protocol, laboratory tests were not scheduled for months 5, 7, and 9. B, number of patients with nonmissing values
at baseline, n = 73 and n = 72 for ALT and AST elevations, respectively.
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